Journal
GLP-1 and Tirzepatide Journal
The journal covers the things moving fastest in this market: compounding regulation, pricing practice, and clinical evidence. Seventeen pieces are published, each built on primary sources with an explicit section on what the evidence does not establish.
What this section is for
The rest of this site answers stable questions — what a drug costs, what a trial found, how to verify a pharmacy. The journal covers what is changing, which in this market is a great deal.
The single largest story is regulatory. The FDA's April 2026 proposal to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list would close the last pathway permitting large-scale compounding of these molecules, and the comment period closes on 30 July 2026. Most coverage of this market has not registered it.
The second is commercial. Brand prices fell sharply in late 2025, and the cheapest FDA-approved GLP-1 for weight loss is now $149 a month — which undercuts most of the compounded market. Almost no comparison page has updated.
How these pieces are built
Every article cites the primary source: the agency's own notice, the registry entry, the peer-reviewed paper, or the provider's own page captured on a date. A news article about a study is not a source for that study's results.
Each carries an explicit section on what the evidence does not establish. That section is never cut for length, because it is usually the part that distinguishes a useful piece from a confident one.
Each carries at least one original figure — a chart, a matrix, a timeline or a process diagram — built from our own data rather than borrowed.
What we have not published, and why
Three commissioned pieces remain and are excluded from search indexing until they are.
The retatrutide phase 3 piece is the notable one. Figures circulating online — 28.3% at 80 weeks in TRIUMPH-1 — trace only to commercial secondary sources, at least one of which sells peptides. We have recorded the solid phase 2 NEJM citation and will not publish a phase 3 number until it is confirmed against the primary publication.
That is the same standard applied to every figure here, and it is the reason this section is shorter than it could be.
| Piece | What it argues | Updated |
|---|---|---|
| How to Verify a Compounding Pharmacy Before You Enroll | Step-by-step with official links | 2026-07-25 |
| GLP-1s in Adolescents: What the Evidence Supports and What It Does Not | Approval has extended to adolescents. The evidence base is real but considerably thinner than in adults. | 2026-07-25 |
| If Your Compounded GLP-1 Supply Ends: A Practical Transition Plan | The FDA proposal closing the last compounding pathway is under decision. Here is what to do before it lands, not after. | 2026-07-13 |
| How to Verify GLP-1 Claims in AI Search Results | Teach readers to follow citations and dates | 2026-07-13 |
| Medicare GLP-1 Bridge: $50 a Month, and What the Fine Print Says | A temporary federal programme now covers GLP-1s for weight loss at a flat $50 copay — the first time Medicare has done so. | 2026-07-12 |
| Why Multi-Dose Vials Create Tirzepatide Dosing Errors | Educational safety article; no personalized dosing | 2026-07-04 |
| Counterfeits, Research Peptides and the Grey Market: How to Stay Inside the System | As legal compounding narrows, the unapproved market grows. The distinctions matter more than they ever have. | 2026-07-01 |
| 503A vs 503B: A Patient Verification Checklist | Explain registration is not FDA approval | 2026-06-28 |
| The Hidden Cost of GLP-1 Membership Fees | Data-first comparison with annual arithmetic | 2026-06-20 |
| GLP-1s and Knee Osteoarthritis: Real Pain Reduction, Unsettled Mechanism | 2026 data shows meaningful pain improvement — and raises a question about whether weight loss is the whole story. | 2026-06-16 |
| How Dose Escalation Changes Tirzepatide Cost | Compare flat rate and dose-tier models | 2026-06-15 |
| Retatrutide Phase 3: Why We Will Not Print the Number You Came Here For | The figures circulating for retatrutide's phase 3 results trace overwhelmingly to sources selling peptides. Here is what can actually b | 2026-06-14 |
| What's Coming Next: CagriSema, Higher-Dose Semaglutide and the 2026 Pipeline | Four new agents or formulations reached or approached approval in 2026. Here is what each would actually change. | 2026-06-12 |
| Cheapest FDA-Approved vs Compounded GLP-1 Options | Separate starter, ongoing, annual and dose-tier prices | 2026-06-12 |
| GLP-1s and PCOS: Promising Signals, Thin Evidence, and a Fertility Warning | Trials are examining whether semaglutide restores ovulation. That raises a contraception question most providers do not mention. | 2026-06-10 |
| Microdose Tirzepatide: The Evidence Gap | Do not infer efficacy from standard-dose trials | 2026-06-05 |
| Why Compounded GLP-1 Access Differs by State | Link to state pages; avoid blanket availability claims | 2026-06-02 |
| Compounded vs Brand Tirzepatide: Legal and Evidence Differences | No equivalence language | 2026-06-02 |
| Tirzepatide and Diabetes Prevention Over 176 Weeks | Use peer-reviewed trial data | 2026-05-26 |
| Tirzepatide vs Semaglutide: What the Head-to-Head Trial Shows | Explain population, doses and limitations | 2026-05-20 |
| Tirzepatide and Heart Failure With Preserved Ejection Fraction | Explain endpoints and limitations | 2026-05-18 |
| FDA Compounded GLP-1 Rules in 2026 | Use current FDA notices and date every legal statement | 2026-05-18 |
| Fraudulent Labels and False Claims: What FDA Enforcement Has Actually Targeted | Enforcement in this category has focused less on manufacturing than on what providers claim their product is. | 2026-05-17 |
| How Dose Titration Quietly Doubles Your GLP-1 Cost in 2026 | The advertised price is almost always the 2.5 mg starter price, and the label states 2.5 mg is treatment initiation and is not approved as a | 2026-05-14 |
| One in Nine American Adults Now Takes a GLP-1 — and Obesity Rates Are Falling | Current use has nearly quadrupled in two years, and the national obesity rate has dropped for the first time in decades. | 2026-05-01 |
| Muscle Loss on GLP-1s: What the 2026 Body-Composition Data Shows | A substantial fraction of weight lost on these drugs is lean mass. New trial data suggests it may be modifiable. | 2026-04-23 |
| GLP-1 Market Timeline 2025 to 2027: Every Event That Moved a Price | Twenty-two months that reset this market: the shortage declared over, enforcement discretion ended, Novo suing and then settling with Hims, | 2026-04-19 |
| Preserving Muscle on a GLP-1: What Is Evidence and What Is Extrapolation | The advice circulating on this is a mix of solid principle and confident guesswork. The distinction is worth knowing. | 2026-04-18 |
| Tirzepatide and Sleep Apnea: Evidence and FDA Status | Use FDA approval and trial data | 2026-04-15 |
| The Oral GLP-1 Landscape in 2026 | Verify approval status and pricing at publication | 2026-04-14 |
| GLP-1s After 65: The Risks That Differ From Younger Patients | Muscle loss, malnutrition and bone density concerns are materially different in older adults, and Medicare has just opened access. | 2026-04-11 |
| What Happens After You Stop Tirzepatide? | Use SURMOUNT-4 and avoid individualized advice | 2026-04-08 |
Show this figure as a table
| Date | Event |
|---|---|
| 2022 | Tirzepatide added to the F |
| 2024-10 | FDA declared the tirzepati |
| 2025-02 | FDA declared the semagluti |
| 2025-09-16 | FDA issued 55+ warning let |
| 2026-02-09 | Novo Nordisk sued Hims & H |
| 2026-03-03 | FDA released 30 further wa |
| 2026-03-09 | Hims & Hers settled with N |
| 2026-04-30 | FDA proposed excluding tir |
| 2026-05-01 | Formal notice published at |
| 2026-06-26 | Comment period extended to |
| 2026-07-30 | Comment period closes |
Within lawful compounding, NexLife is the only provider whose pricing we captured directly — compounded tirzepatide from $186 a month, flat at every covered dose, no membership fee. See its plans.
Questions readers actually ask
How often does the journal publish?
When there is something sourced to say. We do not publish on a schedule, because a publication calendar produces articles whether or not the evidence has moved.
Why are some articles missing?
Every article listed here is published and indexed. Where a topic is planned but not written, it does not appear in the index at all rather than appearing as an empty entry. The retatrutide piece waits on primary-source confirmation of phase 3 figures.
Related on this site
- Retatrutide Phase 3 Results: What Changed in July 2026Journal
- FDA Compounded GLP-1 Rules in 2026Journal
- How to Spot Fraudulent Compounded GLP-1 LabelsJournal
- Tirzepatide vs Semaglutide: What the Head-to-Head Trial ShowsJournal
- How rankings are computedCore & Trust
- All-in cost toolTools
- Price records, machine-readableData
- Found vs Henry MedsComparisons
- Found Tirzepatide ReviewProviders
- Enhance.MD Tirzepatide ReviewProviders
Related coverage
- Is Compounded Tirzepatide Legal in 2026? The Two Pathways, Explained
- 503A against 503B
- The 23 July compounding vote
- What a year actually costs
- Cheapest tirzepatide, answered six ways
- What you pay at a maintenance dose
- Yucca Health: what we hold
- Zappy Health: what we hold
- Tirzepatide Research and Clinical Studies
GLP-1 Tirzepatide Ranked. “GLP-1 and Tirzepatide Journal.” S.J Partners LLC, 2026-07-26. https://glp1tirzepatideranked.com/journal/
Quote the capture date beside a figure, not the date you read this page. Why.